Details for Patent: 7,320,999

Title:	Dimethyl fumarate for the treatment of multiple sclerosis
Abstract:	The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s):	Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee:	Fumapharm AG (Luzern, CH)
Filing Date:	Jul 17, 2002
Application Number:	10/197,077
Claims:	1. A method of treating multiple sclerosis comprising treating a patient in need of treatment for multiple sclerosis with an amount of a pharmaceutical preparation effective for treating said multiple sclerosis, wherein the only active ingredient for the treatment of multiple sclerosis present in said pharmaceutical preparation is dimethyl fumarate. 2. The method of claim 1, wherein 10 to 300 mg of dimethyl fumarate is present in said pharmaceutical preparation. 3. The method of claim 2, wherein said pharmaceutical preparation is provided in one or more capsules. 4. The method of claim 1, wherein at least 50 mg of dimethyl fumarate is present in said pharmaceutical preparation. 5. The method of claim 4, wherein at least 110 mg of dimethyl fumarate is present in said pharmaceutical preparation. 6. The method of claim 5, wherein at least 120 mg of dimethyl fumarate is present in said pharmaceutical preparation. 7. The method of claim 1, wherein 50 mg of dimethyl fumarate is present in said pharmaceutical preparation. 8. The method of claim 1, wherein 110 mg of dimethyl fumarate is present in said pharmaceutical preparation. 9. The method of claim 1, wherein 120 mg of dimethyl fumarate is present in said pharmaceutical preparation. 10. The method of claim 1, wherein the pharmaceutical preparation is formulated for oral administration. 11. The method of claim 1, wherein the pharmaceutical preparation is formulated as a solid dosage form. 12. The method of claim 1, wherein the pharmaceutical preparation is in the form of microtablets. 13. The method of claim 12, wherein the microtablets are enteric-coated. 14. The method of claim 13, wherein the microtablets have a mean diameter in the range of 0.3 mm to 2.0 mm, exclusive of any coating on the microtablets. 15. The method of claim 14, wherein the microtablets have a mean diameter of 2.0 mm, exclusive of any coating on the microtablets. 16. The method of claim 1, wherein the pharmaceutical preparation is in the form of a capsule containing 120 mg of dimethyl fumarate in the form of enteric-coated microtablets having a mean diameter in the range of 0.3 mm to 2.0 mm, exclusive of any coating on the microtablets. 17. The method of claim 1, wherein the pharmaceutical preparation comprises one or more carriers. 18. The method of claim 1, wherein the pharmaceutical preparation comprises one or more excipients.